1155846-86-8

Basic information

• Product Name: MK -1439 intermediate
• Synonyms: MK -1439 intermediate;Benzonitrile, 3-chloro-5-[[1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl]oxy]-;3-Chloro-5-[[1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl]oxy]benzonitrile
• CAS NO: 1155846-86-8
• Molecular Formula: C₁₃H₆ClF₃N₂O₂
• Molecular Weight: 314.6471496
• Product Categories: intermediate
• Mol File: 1155846-86-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 409.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.54±0.1 g/cm3(Predicted)
• PKA: 10.03±0.10(Predicted)
• CAS DataBase Reference: MK -1439 intermediate(CAS DataBase Reference)
• NIST Chemistry Reference: MK -1439 intermediate(1155846-86-8)
• EPA Substance Registry System: MK -1439 intermediate(1155846-86-8)

Safety Data

• Hazardous Substances Data: 1155846-86-8(Hazardous Substances Data)

Usage

Uses

MK -1439 intermediate belongs to heterocyclic derivatives and can be used as pharmaceutical intermediates.

Upstream product

• 1155846-88-0 3-(3-bromo-5-chlorophenoxy)-4-(trifluoromethyl)pyridin-2(1H)-one 
• 544-92-3 copper(I) cyanide 
• 557-21-1 zinc(II) cyanide 
• 1155846-88-0 3-(3-bromo-5-chlorophenoxy)-4-(trifluoromethyl)pyridin-2-ol 
• 1338226-06-4 2-chloro-3-(3-chloro-5-iodophenoxy)-4-(trifluoromethyl)pyridine 
• 1155846-87-9 3-(3-bromo-5-chlorophenoxy)-2-chloro-4-(trifluoromethyl)pyridine 
• 56962-04-0 3-bromo-5-chlorophenol 
• 628692-22-8 2-chloro-3-fluoro-4-(trifluoromethyl)pyridine 
• 1338226-07-5 3-(3-chloro-5-iodophenoxy)-4-(trifluoromethyl)pyridin-2-ol 
• 625-99-0 3-iodochlorobenzene 
• 6575-00-4 3,5-dichlorobenzonitrile 
• 1613307-28-0 (2E/Z,4E)-ethyl 2-(3-chloro-5-cyanophenoxy)-5-ethoxy-3-(trifluoromethyl)penta-2,4-dienoate 
• 1613307-27-9 ethyl 2-(3-chloro-5-cyanophenoxy)acetate 
• 473923-97-6 3-chloro-5-hydroxybenzonitrile 

Downstream Products

• 1155847-32-7 tert-butyl 3-{[3-(3-chloro-5-cyanophenoxy)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl]methyl}-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 
• 1155846-69-7 N-[4-(aminosulfonyl)-2-chlorophenyl]-2-[3-(3-chloro-5-cyanophenoxy)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl]acetamide 
• 1338226-05-3 3-chloro-5-((2-oxo-1-((5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile 
• 1338226-19-9 3-{[5-bromo-2-hydroxy-4-(trifluoromethyl)pyridin-3-yl]oxy}-5-chlorobenzonitrile 
• 1338225-98-1 3-Chloro-5-({1-[(4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile 

Relevant articles and documents

Characterization of impurities of HIV NNRTI Doravirine by UHPLC-high resolution MS and tandem MS analysis

World Health Organization estimates that 34 million individuals globally are living with Human Immunodeficiency Virus (HIV). Doravirine is a non-nucleoside reverse transcriptase inhibitors (NNRTI) being evaluated by Merck for the treatment of HIV-1 infect

Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs

A novel series of acetamide-substituted derivatives and two prodrugs of doravirine were designed and synthesized as potent HIV-1 NNRTIs by employing the structure-based drug design strategy. In MT-4 cell-based assays using the MTT method, it was found that most of the new compounds exhibited moderate to excellent inhibitory potency against the wild-type (WT) HIV-1 strain with a minimum EC50 value of 54.8 nM. Among them, the two most potent compounds 8i (EC50 = 59.5 nM) and 8k (EC50 = 54.8 nM) displayed robust activity against WT HIV-1 with double-digit nanomolar EC50 values, being superior to lamivudine (3TC, EC50 = 12.8 μM) and comparable to doravirine (EC50 = 13 nM). Besides, 8i and 8k shown moderate activity against the double RT mutant (K103N + Y181C) HIV-1 RES056 strain. The HIV-1 RT inhibition assay further validated the binding target. Molecular simulation of the representative compounds was employed to provide insight on their structure-activity relationships (SARs) and direct future design efforts. Finally, the aqueous solubility and chemical stability of the prodrugs 9 and 10 were investigated in detail.

PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS

The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase and HIV replication, and the treatment of human immunodeficiency virus infection in humans.